Back to search

Article

Vemurafenib Sensitizes Melanoma Cells to Temozolomide by Downregulating MGMT Expression.

2020-10-01

Abstract excerpt

<title>Abstract</title> <p>BackgroundThe alkylating agent temozolomide (TMZ) is widely used to treat melanoma in clinical practice. However, cells expressing the DNA repair enzyme O<sup>6</sup>-methylguanine-DNA methyltransferase (MGMT) are highly resistant to this drug. Vemurafenib (vMF), a targeted BRAF kinase inhibitor, is applied to treat BRAF-V600 mutant metastatic melanoma. Studies have suggested that block...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bbb3586d-3dbc-5ced-ab24-3eed90d664f6
DOI
10.21203/rs.3.rs-83301/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Vemurafenib Sensitizes Melanoma Cells to Temozolomide by Downregulating MGMT Expression.DOI 10.21203/rs.3.rs-83301/v1
Vemurafenib.Semantic proximity
[Progress of anti-tumor study based on BRAF].Semantic proximity
Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanomaSemantic proximity
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.Semantic proximity
Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy ResistanceSemantic proximity
Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.Semantic proximity
Vemurafenib therapy for stage IV melanoma with V600G-mutation.Semantic proximity
Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.Semantic proximity
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.Semantic proximity
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.Semantic proximity
MGMT Expression Predicts PARP-Mediated Resistance to TemozolomideSemantic proximity
Recent Approaches to Improve the Antitumor Efficacy of TemozolomideSemantic proximity
Select a neighboring publication to make it the new centre.